EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo

Raphaël Saporta iD, Natália Tassi, Veronica Biordi, Olga Ticha, Aghavni Ginosyan iD, Irena Loryan iD, Elisabet I Nielsen iD, Isabelle Bekeredjian-Ding iD, Bernhard Kerscher iD, Lena E Friberg iD

Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)

DOI: 10.1128/aac.01788-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Raphaël Saporta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo antibiotic pharmacokinetic-pharmacodynamic (PKPD) properties are typically studied in neutropenic infection models, limiting the understanding of interactions between immune cells and antibiotics. This study aimed to characterize the impact of immune status on meropenem PKPD and dose-response in a mouse lung infection model, and to quantify the relative contribution of immune response and meropenem to bacterial killing. Meropenem PK was analyzed in plasma and epithelial lung fluid, and bacterial counts were monitored over 24 h following 40 or 300 mg/kg meropenem doses every 4 h in a mouse lung infection model with varying immunosuppression levels (neutropenic, intermediate, or immunocompetent). A PKPD model was developed to quantify bacterial killing by the immune response and meropenem over time. Dose-fractionation studies were simulated to investigate meropenem dose-response in different immune states. Observed differences in meropenem concentration-time profiles were explained by a higher volume of distribution in immunocompetent mice. The immune response was described by phagocytosis and digestion processes. The meropenem effect was best quantified based on plasma concentrations, with a maximal killing rate of 0.934 h −1 and EC 50 = 1.62 mg/L. The lower contribution of meropenem to bacterial killing in intermediate and immunocompetent conditions was explained as a lower fraction of bacteria being affected by meropenem. In simulations, the immune status impacted PKPD target derivation. The developed model characterized differences in meropenem PK between neutropenic and immunocompetent in vivo infection models and quantified the contributions of immune response and meropenem to bacterial killing, with a reduced effect of meropenem in immunocompetent systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemAnti-Bacterial AgentsAnimalsMiceMicrobial Sensitivity TestsFemaleLungNeutropeniaDose-Response Relationship, Drug

Stichwörter der Autor:innen

immune responsemeropenemmodelingpharmacokinetics-pharmacodynamics

Substanzen

MeropenemAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Division of Infectious Diseases, Paul-Ehrlich-Institut, Langen, Germany.

ORCID-Profile: Raphaël Saporta, Aghavni Ginosyan, Irena Loryan, Elisabet I Nielsen, Isabelle Bekeredjian-Ding, Bernhard Kerscher, Lena E Friberg

Förderung

  • H2020 Marie Skłodowska-Curie Actions
  • Swedish Research Council

Zitieren

APA

Saporta, R., Tassi, N., Biordi, V., Ticha, O., Ginosyan, A., Loryan, I., Nielsen, E. I., Bekeredjian-Ding, I., Kerscher, B., & Friberg, L. E. (2026). Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01788-25

Vancouver

Saporta R, Tassi N, Biordi V, Ticha O, Ginosyan A, Loryan I, et al. Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01788-25

BibTeX
@article{Saporta2026,
  author = {Saporta, Raphaël and Tassi, Natália and Biordi, Veronica and Ticha, Olga and Ginosyan, Aghavni and Loryan, Irena and Nielsen, Elisabet I and Bekeredjian-Ding, Isabelle and Kerscher, Bernhard and Friberg, Lena E},
  title = {Pharmacokinetic-pharmacodynamic modeling to evaluate the relative impact of immune response and meropenem on bacterial killing in vivo},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {4},
  doi = {10.1128/aac.01788-25}
}
Kostenlos starten →